The 6th iPSC Drug Development Summit is the only meeting exclusively focused on advancing iPSC-based cell therapies, end-to-end. It brings together leaders such as Aspen Neuroscience, BlueRock Therapeutics, and Vertex Pharmaceuticals, who are building programs today, spanning discovery, preclinical development, process development, CMC, and regulatory strategy. By joining the summit, attendees can learn how iPSC therapies are being designed for scale and clinical success from the very beginning. After years of uncertainty, the field is re-emerging on the 20th anniversary of iPSC technology, with stronger clinical data than ever before. The room will hear directly from companies driving this progress, including Century Therapeutics, advancing its Type 1 diabetes program into the clinic, and BlueRock Therapeutics, generating positive data as it moves into Phase III. With investment at its strongest point in years, and the likes of Aspen Neuroscience and Century Therapeutics securing $100 million-plus in funding rounds, the focus has shifted decisively from promise to performance. This summit is designed to help teams understand what “right execution” looks like today, with the invest panel and roundtable aiming to delve into how those decisions will shape the next decade of iPSC therapy development.